๐ข ๐๐๐๐ ๐๐: $Tempus AI(TEM.US) FDA Approves Tempus AIโs xT CDx for Tumor-Only Genomic Profiling
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค FDA grants ๐ญ๐ฎ๐ฆ๐จ๐ซ-๐จ๐ง๐ฅ๐ฒ approval for Tempus AIโs ๐ฑ๐ ๐๐๐ฑ platform.โค Tempus becomes first lab with FDA-approved ๐ญ๐ฎ๐ฆ๐จ๐ซ-๐จ๐ง๐ฅ๐ฒ and ๐ญ๐ฎ๐ฆ๐จ๐ซ-๐ง๐จ๐ซ๐ฆ๐๐ฅ CDx profiling.โค xT CDx is a ๐๐๐-๐ ๐๐ง๐ assay for comprehensive solid tumor profiling.โค Approval allows testing when matched blood or saliva samples are unavailable.โค Platform serves as a ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐จ๐ง ๐๐ข๐๐ ๐ง๐จ๐ฌ๐ญ๐ข๐ for certain colorectal cancer therapies.โค Tempus plans to migrate its DNA tumor portfolio to ๐ ๐๐-๐๐ฉ๐ฉ๐ซ๐จ๐ฏ๐๐ assays.โค Company expects an estimated $๐๐๐ ๐๐๐ benefit beginning in ๐๐๐๐The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments